Patho final exam review (Module 1-Medicinal Chemistry) Flashcards

1
Q

define pharmacophore

A

drugs that bind to the same target share a similar structural motif-this motif is necessary for binding to the receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

define the structure-activity relationship

A

properties of a drug depend on the chemical constituents of the molecule–by modifying the structure one can change the drug properties

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

list chemical properties of drugs that can be deduced from the structure and ones that affect their biological activities, ones that are affected by the change in pH

A

-pH affects ionization
structure [size, ionization, solubility, hydrophobicity, stereochemistry]
activity [membrane permeability, target binding, metabolism, excretion]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

identify ionizable groups in drug structures

A

weak acids and bases pka less than or higher than 7
-rings, carboxyls, phenol, guanidine, alkyl amines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

estimate the degree of drug ionization at a given pH using Henderson-Hasselbalch equation

A

pH<pKa is more acidic and more in acid form; protonated
pH>pKa is more basic and more in basic form; deprotonated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Predict the range of pH where a drug would be more soluble in water

A

water is polar
-make more acidic to improve solubility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

At pH 6.4, what is the ration of this drug in the acid form (neutral) to that in the base form (negatively-charged)? ibuprofen pKa 4.4
A. 100:1
B. 10:1
C. 1:1
D. 1:10
E. 1:100

A

E. 1:100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the different modes of permeation into the body?

A

Intercellular junctions, Lipid cell membranes, Transporters, Endocytosis and exocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

identify hydrophobic and hydrophilic groups in a drug structure

A

hydrophobic- methyl, chloro, phenyl, hexyl, cyclohexyl
hydrophillic- alcohol, carboxylic acid, amine, ketone, amide, ester

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

identify hydrogen bond donors and acceptors in a drug structure

A

donors- OH,NH
acceptors- O,N

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

explain how logP values affect the ability of drugs to reach target sites

A

-orally active drugs are relatively small and moderately lipophilic; hydrophobic drugs are sticky and bind to its drug better to target
-logP values are usually between -1 and 4
logP < 0
logP = 0 equal distribution
logP > 0 drug factors octanol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

explain why the relationship of drug effectiveness versus logP is parabolic

A

the relationship is parabolic because too hydrophobic or not being hydrophobic both can inhibit drug activity the same amount

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

calculate logP of a drug molecule from the pi value of its constituent groups

A

ClogP
-hydrophobic groups increase LogP (+)
-hydrophilic groups decrease LogP (-)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

estimate logD using logP an pKa at a given pH

A

Drug HA is acidic with logP= 2 and pKa=4
-at pH=1 D~P
-at pH=7 D«P
Drug B is a basic drug with logP= 2 and pKa=7
-at pH= 10 D~P
-at pH= D«P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Predict the efficiency of passive diffusion of a drug with a known pKa at a given pH

A

more neutral the compound is, the more can participate in passive diffusion
ratio of 1000:1 means 99.9% is neutral and can penetrate quicker/faster
equal concentration can cross at slower rate because only 0.1% is truly neutral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

predict where a drug will be absorbed in the digestive system based on the drug’s pKa value

A

drugs are absorbed in jejunum when pH is between 5-7
acidic drugs are absorbed in stomach where pH is 1-3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Define Hammett’s sigma values and estimate the electronic effects of substituent groups on drug ionization using hammett’s sigma values, also electron withdrawing and electron-donating groups

A

hammett’s sigma defines electronic effects on a functional group
positive sigma value- electron-withdrawing group (more acidic & lower pKa)
negative sigma value- electron-donating group (less acidic & higher pKa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what is the difference between inductive effect and resonance effect

A

withdrawing effect- negative charges can be stabilized and make molecule more acidic; effect becomes weaker by going through multiple bonds
(inductive effect)
resonance effect- observed with pi bonds, electronegative atoms with withdrawing effects, only occurs in ortho and para positions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how do electronic effects of substituent groups affect ionization, acidity and basicity

A

basic- electron-donating groups make the molecule more basic; electron-withdrawing make the molecule less basic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

determine R/S and E/Z notations for drugs from their structures

A

cis- Z (same side)
trans- E (against/across from eachother)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what are the differences between R/S, d/l, and D/L nomenclature systems

A

R/S -by absolute configuration, primary method for drugs. R (clockwise; right) S (counterclockwise; left)
d/l or +/- system- by optical rotation, experimentally determined, depends on solution condition
D/L- by relative configuration to glyceraldehyde; obsolete and only used for amino acids and sugars

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

list factors other than receptor binding that result in different biological properties of drug enantiomers

A

-permeation by transporters
-nonspecific binding to serum proteins
-metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

when a pair of stereoisomers are given, determine whether they are enantiomers, diastereomers, or geometric isomers

A

enantiomers- (1R, 2S) and (1S, 2R); (1R,2R) and (1S,2S)
diastereomers- (1R,2S) and (1R,2R); (1S,2R) and (1S,2S)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the KD value from a binding isotherm

A

KD- dissociation equilibrium constant
smaller the KD, the stronger the binding is
KD= (D)(R)/(DR)
When [D]=KD 50% of all receptors are occupied
When [D] &laquo_space;KD ~ 0
When [D]&raquo_space; KD ~ 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

calculate delta G(D) from KD & vice versa

A

DeltaG ~ -1.4 x LogKD (kcal/mol)
10^-6 (KD) = 8.4 (DG)
10^-7 (KD) = 9.8 (DG)
10^-8 (KD) = 11.2 (DG)

26
Q

explain characteristics of type of interactions between drugs and receptors & types of interactions between drugs and receptors from a given structure

A

Hydrophobic interactions- attraction between nonpolar groups in water; most common type of interactions in protein-ligand complexes; surface area of nonpolar surface is reduced
electrostatic interactions- attraction between +/- charges; water is a dipole, loves ions & dipoles can also be in proteins (backbone amide, a-helix)
Hydrogen bonds- O and N;ionic H-bonds are stronger than neutral H-bonds
aromatic rings- attractions are between electron-rich and electron-deficient regions (can be affected by EWG and EDGs)
pi stacking- parallel stacking of aromatic rings
T stacking- edge to face
Cation-pi interaction- Interaction between a positive charge and an aromatic ring

27
Q

explain the concept of QSARS (quantitative structure-activity relationships)

A

if you change structure you change the activity; uses mathematics to describe structure activity relationships and can tell roughly if new drug is better or not

28
Q

antimetabolities, structure-based drug design, High-throughput screen, Isosteric replacement, Prodrugs

A

antimetabolites- analogs of endogenous metabolites (can act as inhibitors). will compete with a metabolite in reactions
structure-based drug design- drug designed based on 3-D structure of a target protein
Isosteric replacement- improves pharmacokinetics, improve selectivity, reduce side effects, simplify the synthesis process, avoid patent issues (groups not in pharmacophore are replaced with bioisostere)
Prodrug- inactive or carrier form of a drug that is transformed in vivo (enzymatically) to the active drug form (prolong/shorten duration of drug, localize drug to a specific target site, advantage of active transport process, formulation problem, decrease toxicity, side effects)

29
Q

bioisoteres explain their uses

A

functional groups/atoms with similar steric and electronic properties with similar effects too

30
Q

pharmacology, pharmacodynamics & pharmacokinetics

A

Pharmacology- science of interactions of chemical compounds with biological systems
Pharmacodynamics- the study of the biochemical and physiological effects of drugs and the mechanisms of their actions
Pharmacokinetics- the study of absorption, distribution, biotransformation, and elimination of xenobiotics

31
Q

identify the sites of drug actions (including receptors)

A

types of drug interactions- Orthosteric: agonist, antagonist, partial agonist, inverse agonist
allosteric- PAMs,NAMs
-extracellular, intracellular, on the cell surface

32
Q

law of mass action & receptor occupancy

A

-law of mass action defines drug-receptor interaction
-effect of a drug is directly proportional to the amount of drug-receptor complex formed
rate of association =Kon [D][R]
rate of dissociation =Koff [DR]
KD (dissociation constant)
-the LOWER the KD the HIGHER the affinity
-KD is the concentration of ligand that will bind half the receptors at steady state

33
Q

outline components in a receptor binding assay

A

receptor + radio-labeled ligand then filtered
-non-specific line on binding analysis
radio-labeled ligand competes for same sight as normal ligand

34
Q

principles of receptor binding to measure affinity

A

how tightly it binds
-sometimes 100% binding is not best option
-can use data to get IC50 and then use cheng-prusoff to get Ki

35
Q

graphical data for pharmacological profiling

A

can test several unlabeled compounds to compute Ki for each compound
-can calculate rank affinity
CHENG-PRUSOFF: Ki=IC50/[1+L/KD]

36
Q

apply receptor affinity to receptor selectivity

A

affinity can be used to show selectivity but best affinity for something does not mean best selectivity
-determined by ratio
-higher number means higher selectivity

37
Q

describe the relevance of Bmax to drug action

A

Bmax is an estimated number of receptors in a given tissue
-values are determined through saturation binding studies
-are independent of the ligand
-can influence downstream signaling events

38
Q

Identify and differentiate between the five classes of receptors

A

intracellular receptor
transmembrane receptor
RTKs; cytokine receptors
Ion channel
GPCRs

39
Q

describe the effects of allosteric modulators on ion channels and GPCRs

A

lots of allosteric binding sites on these molecules to allow for changes to the receptor and its binding (can have inhibitory effect)

40
Q

describe the features for G protein activation

A

-extracellular ligand is detected by the cell-surface receptor (R)
-receptor triggers activation of G protein (G)
-activate G protein changes activity of the effector (E) can be enzyme or ion channel

41
Q

effects of subtypes of G proteins

A

Ga(stimulatory)-activates adenylyl cyclases, inhibits Src family tyrosine kinases
Ga(inhibitory)-inhibits adenylyl cyclases, activates phosphodiesterases
Ga(q/11)- activates Phospholipase C
Ga(12/13)- recruits Rho guanine exchange factors(RhoGEFs)
Gby- inhibits adenylyl cyclase, recruits GRK2&3, activates PI3Ky, ion channels (Ca and K)

42
Q

compare signaling of the second messengers and arrestin

A

Second Messengers: cAMP (adenylyl cyclase effector enzyme)
Phospholipase C (PLC) results in release of phosphoinositides and diacylglycerol
cGMP effector enzyme is guanyl cyclase
B arrestins serve as an adaptor protein to link activated GPCRs to MAP kinase pathway
B-arrestin can uncouple receptor from G protein (desensitization) also endocytosis (recycling, lysosomal degradation) and signaling

43
Q

describe the mechanism and consequence of receptor desensitization

A

Heterologous desensitization involves the activation of one GPCR can result in the inhibition of another (Gi-linked)
Homologous desensitization involves only the activated GPCRs are “turned off” or desensitized

44
Q

assess ligand-receptor concentration response curves for functional selectivity

A

functional selectivity requires that the receptor couple to multiple signal transduction pathways (G protein & B arrestin)
*Prefers one pathway heavily over others but can do multiple pathways (biased)

45
Q

use of the concept of functional selectivity to design better drugs

A

can be used to avoid a certain pathways and its negative effects with the drug

46
Q

What is the difference between agonist and antagonist binding

A

-binding of agonist results in induced fit that activates the receptor
-binding of an antagonist results in a different induced fit that does not activate the receptor

47
Q

identify and compare dose response curves for each type of ligand in the “ligand spectrum”

A

full inverse agonist -100%
silent antagonist- 0%
full agonist- 100%
super agonist- 100+%

48
Q

use graphical data to compare potency and efficacy for active ligands

A

potency- dose of a drug required to produce a particular effect of given intensity
efficacy- biological response resulting from the drug-receptor interaction is termed efficacy
strong agonist has high affinity and high efficacy

49
Q

describe the concept of a partial agonist

A

produces a reduced response even at full receptor occupancy, will not produce same maximal effect as a full agonist regardless of concentration

50
Q

apply the concept of partial agonist theory to managing drug therapy

A

as more partial agonists are added to the mixture, full agonists are being displaced which can help in drug therapy to give appropriate response

51
Q

describe the features of an inverse agonist

A

-produces opposite response of an agonist
-full and partial inverse agonists both exist
-stabilizes inactive form of the receptor

52
Q

compare reversible competitive and irreversible, non-competitive inhibition

A

competitive (REVERSIBLE) -antagonist combines with the same site on the receptor as the agonist; antagonism can be reversed by increasing the dose of the agonist
noncompetitive (partially reversible) -antagonist produces its effect at a site of the receptor other than the site used by the agonist; agonist and noncompetitive antagonist do NOT compete with eachother for single binding site
IRREVERSIBLE antagonist- will usually bind to the same site as the agonist, will not be readily displaced-generally caused by covalent reaction between antagonist and receptor

53
Q

use the concept of spare receptor to explain drug action

A

-maximal response is achieved without 100% occupancy of available receptors
-important in action of irreversible antagonists (heart, brain, etc.)
-system/tissue dependent; cells can have lots of reserve or none

54
Q

describe functional and chemical antagonism

A

-functional antagonism: two drugs influence a physiological system but in opposite directions; both drugs can elicit response at same time
-chemical antagonism: chemical reaction occurs between an agonist and an antagonist to form an inactive product; agonist is inactivated proportionally to the extent of the chemical reaction with the antagonist

55
Q

describe the mechanisms of allosteric modulators and their potential benefit in drug therapy

A

-bind at sites unique from the agonist/antagonist
-PAMs can increase potency, efficacy
-NAMs can decrease potency, efficacy

56
Q

define the key means by which drug effect is quantified and compared (onset, intensity, duration)

A

onset- when the drug starts its effects (MEC)
duration of action- how long the drug is active
Intensity- peak effect

57
Q

know the differences between a quantal vs graded drug response

A

quantal response- all-or-none dose-response relationships (anaphylaxis or not; sedated or not)
graded drug response- depends on dose and shows progressively increasing effects with increasing concentrations of the drug

58
Q

calculate and compare the therapeutic index between drugs

A

Therapeutic index= TD50/ED50
TD50 is toxic side effect
ED50 is therapeutic effect

59
Q

describe the factors that modify the effects of drugs

A

-Drug tolerance (occurs by either drug disposition/metabolic tolerance or cellular/pharmacologic tolerance)

60
Q

compare and contrast drug disposition tolerance and pharmacologic tolerance

A

pharmacologic tolerance affects the normal reactivity of the receptor; downregulation of receptors; change in receptor affinity, etc.
drug disposition tolerance affects effectiveness of drug

61
Q

apply cross-tolerance to disease management

A

tolerance develops to one drug and is seen with drugs belonging to the same class; not always complete (basis for opioid rotation)

62
Q

understand the bases for on-target and off-target adverse effects

A